Terbinafine (topical): Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Terbinafine}} | {{Terbinafine}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Overview== | ==Overview== | ||
==Category== | ==Category== | ||
Antifungal | |||
==US Brand Names== | ==US Brand Names== | ||
LamISIL<sup>®</sup> | |||
==FDA Package Insert== | ==FDA Package Insert== | ||
Revision as of 20:59, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Category
Antifungal
US Brand Names
LamISIL®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages